

DESCRIPTION

Source *Spodoptera frugiperda*, Sf 9 (baculovirus)-derived human TGF-beta 3 protein
Ala301-Ser412
Accession # P10600
Produced in an animal component free process (ACFP).
Manufactured and tested under current Good Manufacturing Practice (GMP) guidelines.

N-terminal Sequence Analysis Ala₃₀₁-Leu-Asp-Thr-Asn-Tyr-(Cys)-Phe-Arg-Asn

Structure / Form Disulfide-linked homodimer

Predicted Molecular Mass 12.7 kDa (monomer)

SPECIFICATIONS

SDS-PAGE 12 kDa, reducing conditions
24 kDa, non-reducing conditions

Activity Measured by its ability to inhibit the IL-4-dependent proliferation of HT-2 mouse T cells. Tsang, M. *et al.* (1995) Cytokine 7:389.
The ED₅₀ for this effect is 0.01-0.04 ng/mL.
The specific activity of recombinant human TGF-β3 is approximately 2.2 x 10⁴ IU/μg, which is calibrated against recombinant human TGF-β3 WHO International Standard (NIBSC code: 09/234).

Endotoxin Level <0.01 EU per 1 μg of the protein by the LAL method.

Purity >97%, by SDS-PAGE with silver staining.

Mycoplasma Negative when tested in a ribosomal RNA hybridization assay.

Formulation Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA. See Certificate of Analysis for details.

PREPARATION AND STORAGE



Reconstitution Reconstitute at 50-200 μg/mL in sterile 4 mM HCl.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- A minimum of 6 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, ≤ -20 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

TGFβ3 (transforming growth factor-beta 3) is a member of a TGF-β superfamily subgroup that is defined by their structural and functional similarities (1-5). TGF-β3 and its closely related proteins, TGF-β1 and -β2, act as cellular switches to regulate immune function, cell proliferation, and epithelial-mesenchymal transition (4, 6, 7). The non-redundant biological effects of TGF-β3 include involvement in palatogenesis, chondrogenesis, and pulmonary development (1, 2, 7-9). Human TGF-β3 cDNA encodes a 412 amino acid (aa) precursor that contains a 20 aa signal peptide and a 392 aa proprotein. The proprotein is processed by a furinlike convertase to generate a 220 aa latency-associated peptide (LAP) and a 112 aa mature TGF-β3 (10, 11). Mature human TGF-β3 shows 100%, 99%, and 98% aa identity with mouse/dog/horse, rat, and pig TGF-β3, respectively. TGF-β3 is secreted as a complex with LAP. This latent form of TGF-β3 becomes active upon cleavage by plasmin, matrix metalloproteinases, thrombospondin-1, and a subset of integrins (12). TGF-β3 binds with high affinity to TGF-β RII, a type II serine/threonine kinase receptor. This receptor then phosphorylates and activates type I serine/threonine kinase receptors, TGF-β RI or ALK-1, to modulate transcription through Smad phosphorylation (13-15). The divergent biological effects exerted by individual TGF-β isoforms is dependent upon the recruitment of co-receptors (TGF-β RIII and endoglin) and the subsequent initiation of Smad-dependent or -independent signaling pathways (14, 16, 17).

References:

1. Barrio, M.C. *et al.* (2014) *Cells Tissues Organs*. [Epub ahead of print; PMID 24861080].
2. Doetschman, T. *et al.* (2012) *Genesis* **50**:59.
3. Mittl, P.R. *et al.* (1996) *Protein Sci.* **5**:1261.
4. Sporn, M.B. (2006) *Cytokine Growth Factor Rev.* **17**:3.
5. Wahl, S.M. *et al.* (2006) *Immunol. Rev.* **213**:213.
6. Chang, H. *et al.* (2002) *Endocr. Rev.* **23**:787.
7. Dunker, N. and K. Kriegelstein (2000) *Eur. J. Biochem.* **267**:6982.
8. Jin, J.Z. *et al.* (2014) *Dev. Dyn.* [Epub ahead of print; PMID 25104574].
9. Tang, Q.O. *et al.* (2009) *Expert Opin. Biol Ther.* **9**:689.
10. Derynck, R. *et al.* (1988) *EMBO J.* **7**:3737.
11. Miyazono, K. *et al.* (1988) *J. Biol. Chem.* **263**:6407.
12. Oklu, R. and R. Hesketh (2000) *Biochem. J.* **352 Pt 3**:601.
13. Cui, X.M. and C.F. Shuler (2000) *Int. J. Dev. Biol.* **44**:397.
14. de Caestecker, M. (2004) *Cytokine Growth Factor Rev.* **15**:1.
15. Nakajima, A. *et al.* (2007) *Dev. Dyn.* **236**:791.
16. Iwata, J. *et al.* (2012) *J. Clin. Invest.* **122**:873.
17. Gatzka, C.E. *et al.* (2010) *Cell. Signal.* **22**:1163.

MANUFACTURING SPECIFICATIONS

GMP Proteins

R&D Systems, a Bio-Techne Brand's GMP proteins are produced according to relevant sections of the following documents: WHO TRS, No. 822, 1992 Annex 1, Good Manufacturing Practices for Biological Products; USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and USP Chapter 92, Growth Factors and Cytokines Used in Cell Therapy Manufacturing.

R&D Systems' quality focus includes:

- Manufactured and tested under an ISO 9001:2015 and ISO 13485:2016 certified quality system
- Documented processes and QA control of documentation and process changes
- Personnel training programs
- Raw material testing and vendor qualification/monitoring
- Fully validated equipment, processes and test methods
- Equipment calibration schedules using a computerized calibration program
- Facility maintenance, safety programs and pest control
- Material review process for variances
- Monitoring of stability over product shelf-life

R&D Systems strives to provide our customers with the analytical characteristics of each product so that customers may determine whether our products are appropriate for their research. The Certificate of Analysis provided contains the following lot specific information:

- N-terminal amino acid analysis, SDS-PAGE analysis, and endotoxin level (as determined by LAL assay) performed on each bulk QC lot, not on individual bottlings of each QC lot
- Post-bottling lot-specific bioassay results (compliance with an established range) and results of microbial bioburden testing (using broth culture, Sabourand's dextrose and blood agar plates with results reported at 3 days and at 7 days)
- Mycoplasma testing by ribosomal RNA hybridization assay

Additional testing and documentation requested by the customer can be arranged at an additional cost. Testing may include, but is not limited to, USP <61> bioburden testing, positive identity testing, testing for adventitious agents and testing for residual host cell content.

Production records and facilities are available for examination by appropriate personnel on-site at R&D Systems in Minneapolis, Minnesota USA.

R&D Systems sells GMP grade products for preclinical or clinical *ex vivo* use. They are not for *in vivo* use. Please read the following End User Terms prior to using this product.

Animal Component-Free Process (ACFP) Manufacturing Conditions

R&D Systems Animal Component-Free Process (ACFP) recombinant proteins are expressed in an animal-free certified Sf9 insect cell line using dedicated animal-free raw materials and labware. Production and purification procedures use equipment and media that are confirmed animal-free but performed outside our dedicated animal-free laboratories. Every stage of the manufacturing process follows R&D Systems' stringent Standard Operating Procedures (SOPs). The certified Sf9 insect cell bank has undergone extensive testing to certify the lack of cytopathogens by screening for various viruses, Mycoplasma, and Spiroplasmas using both *in vitro* and *in vivo* testing methods.

[Please read our complete ACFP Statement](#)

PRODUCT SPECIFIC NOTICES

END USER TERMS OF USE OF PRODUCT

The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.

We suggest you print and retain a copy of these End User Terms of Use of Product for your records.

The End User is aware that R&D Systems, Inc. sells GMP products for preclinical or clinical *ex vivo* use and not for *in vivo* use. The End User further agrees, as a condition of the sale of R&D Systems' GMP products that: a) the End User will not use this GMP Product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the Institutional Review Board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.

R&D Systems, Inc. has the right, at its sole discretion, to modify, add or remove any terms or conditions of these End User Terms of Use without notice or liability to you. Any changes to these End User Terms of Use are effective immediately following the printing of such changes on this product insert. The most recent version of these End User Terms of Use of Product may be found at: RnDSystems.com/Legal.

You agree to review these End User Terms of Use of Product to ensure any subsequent use by you of R&D Systems' GMP Products following changes to these End User Terms of Use of Product constitutes your acceptance of all such changes.

TERMS AND CONDITIONS

The following limitation applies to R&D Systems' warranty and liability for damages: All products are warranted to meet R&D Systems' published specifications when used under normal laboratory conditions.

R&D SYSTEMS DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, R&D SYSTEMS DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.

NOTWITHSTANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN R&D SYSTEMS AND PURCHASER FOR THE PURCHASE OF THE PRODUCTS, R&D SYSTEMS' TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO R&D SYSTEMS FOR THE APPLICABLE PRODUCTS. IN NO EVENT WILL R&D SYSTEMS BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.

Full details of R&D Systems' Terms and Conditions of Sale can be found online at: RnDSystems.com/Legal.